The FDA has started a review of GSK’s five-in-one meningococcal vaccine, cueing up a decision in mid-February next year, as it tries to chase down a rival candidate from Pfizer cleared last year.

GSK continues to build the case for its multiple myeloma therapy Blenrep, which was pulled from the US market last year, with another positive phase 3 trial. The BCMA-targeted antibody-drug ...

GSK’s share price has fallen a long way from its one-year high, which has only increased the major undervaluation I’d seen in the stock before that. When investing, your capital is at risk ...

Donald Trump is expected to confirm that the UK will not escape the pain of levies he claims will restore 'fairness' in ...

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...

28th Mar 2025 7:00 am RNS Transaction in Own Shares 27th Mar 2025 7:00 am RNS Transaction in Own Shares 26th Mar 2025 7:00 am RNS Transaction in Own Shares ...

3 Year 68.52% 68.49% 24.34% 26.87% ...

GlaxoSmithKline Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 13/11/1924 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification ...